Targets › HPRT1
1 program from 1 company in 1 trial: 1 Phase 1; Neurology.
Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. (UniProt, P00492)
Open in Phaseline: the race on HPRT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fujita Health University | Inosine Purine nucleoside precursor for uric acid synthesis | HPRT1 | Phase 1 | Parkinson's Disease (PD) | – |
Parkinson's Disease (PD) (1)
small molecule (1)
Fujita Health University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.